Cogent Biosciences Statistics
Want to see COGT full AI Analyst Report?
Cogent Biosciences (COGT) Stock Statistics & Valuation Metrics
Total Valuation
Cogent Biosciences has a market cap or net worth of $5.12B. The enterprise value is $5.06B.
- Market Cap
- $5.12B
- Enterprise Value
- $5.06B
Share Statistics
Cogent Biosciences has 173,994,450 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 173,994,450
- Owned by Insiders
- 3.96%
- Owned by Institutions
- 57.47%
Financial Efficiency
Cogent Biosciences’s return on equity (ROE) is -0.52 and return on invested capital (ROIC) is -38.09%.
- Return on Equity (ROE)
- -0.52
- Return on Assets (ROA)
- -0.35
- Return on Invested Capital (ROIC)
- -38.09%
- Return on Capital Employed (ROCE)
- -0.38
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.27M
- Employee Count
- 258
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Cogent Biosciences is -12.65. Cogent Biosciences’s PEG ratio is -2.08.
- PE Ratio
- -12.65
- PS Ratio
- 0.00
- PB Ratio
- 9.84
- Price to FCF
- -15.67
- Price to Operating Cash Flow
- -15.67
- PEG Ratio
- -2.08
Income Statement
In the last 12 months, Cogent Biosciences had revenue of 0 and earned -328.94M in profits. Earnings per share was -2.04.
- Revenue
- 0
- Gross Profit
- -4.62M
- Operating Income
- -333.36M
- Pretax Income
- -328.94M
- Net Income
- -328.94M
- EBITDA
- -321.29M
- Earnings Per Share (EPS)
- -2.04
Cash Flow
In the last 12 months, operating cash flow was -324.05M and capital expenditures -1.74M, giving a free cash flow of -325.78M billion.
- Operating Cash Flow
- -324.05M
- Free Cash Flow
- -325.78M
- Free Cash Flow per Share
- -1.88
Dividends & Yields
Cogent Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -6.38%
- Earnings Yield
- -8.03%
Stock Price Statistics
- Beta
- 1.15
- 52-Week Price Change
- -17.36%
- 50-Day Moving Average
- 31.74
- 200-Day Moving Average
- 35.41
- Relative Strength Index (RSI)
- 43.38
- Average Volume (3m)
- 2.03M
Important Dates
Cogent Biosciences upcoming earnings date is Mar 16, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Mar 16, 2027
- Ex-Dividend Date
- ―
Financial Position
Cogent Biosciences as a current ratio of 14.23, with Debt / Equity ratio of 39.78%
- Current Ratio
- 14.23
- Quick Ratio
- 14.23
- Debt to Market Cap
- 0.04
- Net Debt to EBITDA
- 0.18
- Interest Coverage Ratio
- -108.87
Taxes
In the past 12 months, Cogent Biosciences has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Cogent Biosciences EV to EBITDA ratio is -12.71, with an EV/FCF ratio of -15.75.
- EV to Sales
- 0.00
- EV to EBITDA
- -12.71
- EV to Free Cash Flow
- -15.75
- EV to Operating Cash Flow
- -15.83
Balance Sheet
Cogent Biosciences has $791.13M in cash and marketable securities with $244.22M in debt, giving a net cash position of $546.91M billion.
- Cash & Marketable Securities
- $791.13M
- Total Debt
- $244.22M
- Net Cash
- $546.91M
- Net Cash Per Share
- $3.14
- Tangible Book Value Per Share
- $2.98
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Cogent Biosciences is $55.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $55.00
- Price Target Upside
- 88.74% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 8
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 0.71%
Scores
- Smart Score
- 6
- AI Score
- 46
